Kurs & Likviditet
|Lista||First North Stockholm|
|Industri||Läkemedel & Handel|
|2022-10-12||Extra Bolagsstämma 2022|
|2022-04-27||Ordinarie utdelning LIPUM 0.00 SEK|
|2021-12-22||Extra Bolagsstämma 2021|
The Scientific Advisory Board of Lipum constitute an invaluable resource of experience from academic research to clinical practice within the field chronic inflammatory diseases. The members contributions are expressed in specific advices along Lipums development, as well as the sharing of deep knowledge in more strategic discussions. An important forum has been the annual workshop with the Lipum team.
Reflecting the progress this year’s workshop will focus on the forthcoming clinical studies in the light of results from the preclinical studies and the non-clinical program.
Meet our Scientific Advisory Board here.
For further information, please contact:
Einar Pontén, CEO
Mobil: +46 70 578 34 95
Lipum AB (publ) is a biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in late preclinical stage supported by solid data for the rare disease juvenile idiopathic arthritis and rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission, email: email@example.com, phone: +46 8 503 000 50.